Latest Breaking News On - எரிக் டூபே - Page 1 : comparemela.com

Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand

Press release content from Business Wire. The AP news staff was not involved in its creation.

New zealandDeric dubeVifor pharmaJulien vignotChris clineAbbas hussainNathalie ponnierSwiss stock exchangeTravere therapeutics incGlobal head corporate communicationsSwiss exchangeExchange commissionVifor pharma groupInvestor relations corporate communicationsFresenius medical carePharma group

Vifor Pharma Group: Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand

Sparsentan is a potential first-in-class treatment to address significant unmet medical need in rare kidney disorders focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)

New zealandDeric dubeVifor pharmaJulien vignotChris clineAbbas hussainNathalie ponnierSwiss stock exchangeTravere therapeutics incGlobal head corporate communicationsSwiss exchangeExchange commissionVifor pharma groupInvestor relations corporate communicationsFresenius medical carePharma group

Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand

Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesNew zealandDeric dubeVifor pharmaJulien vignotChris clineAbbas hussainNathalie ponnierLigand pharmaceuticalsSwiss stock exchangeTravere therapeutics incGlobal head corporate communicationsSwiss exchangeExchange commissionVifor pharma groupInvestor relations corporate communications

07 19 21 -- First-Time CEO Transforms Retrophin Into Travere

07.19.21 First-Time CEO Transforms Retrophin Into Travere On this week s episode of the Business of Biotech, Diamyd Medical President & CEO Dr. Ulf Hannelius talks about developing therapies aimed at preserving and restoring insulin production in Type 1 diabetes patients, plus the why and the how behind the company s choice to manufacture them in-house. Listen now and subscribe so you never miss an episode. Articles Eric Dube, Ph.D., was dubious when an executive recruiter pitched him the CEO position at previously embattled Retrophin (remember Martin Shkreli?). But he took the job in January 2019 and now has guided the $1.5 billion biopharma as it has increased sales, implemented a new diverse and inclusive culture, advanced its pipeline, and adopted a new name (Travere).

Deric dubeMartin shkreliஎரிக் டூபே

07 02 21 -- Is Government-Enabled IP Theft Ever A Good Thing?

07 02 21 -- Is Government-Enabled IP Theft Ever A Good Thing?
lifescienceleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lifescienceleader.com Daily Mail and Mail on Sunday newspapers.

Deric dubeMartin shkreliஎரிக் டூபே